What adjuvant therapy would you recommend for a 90-year-old woman with ER-positive, HER2-positive breast cancer who received neoadjuvant trastuzumab, pertuzumab, and anastrozole, but did not achieve a pathologic complete response?  

The clinical information provided is extremely limited (number of neoadjuvant cycles given, node-negative versus node-positive, RCB, toxicity, comorbidities) to provide a definitive recommendation. Therefore, to continue on current therapy or transition her to ado-trastuzumab, T-DM1, and anastrozole...